Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2a versus conventional management in adults with chronic hepatitis C and Child-Pugh A or B cirrhosis
ISRCTN88008850Phase 3Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Apr 2004
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2a in hepatitis C virus infection and Cirrhosis (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Sustained virological response, Death and 2 more. Started Apr 2004; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C virus infectionCirrhosis
Beyond the preview
Go deeper on ISRCTN88008850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN88008850.